Sign in
Active, not recruitingPhase 2

Safety and Immunogenicity of CVI-VZV-001 in Adults Aged 50 Years and Above

Key facts

Who runs it
Aribio Lab Co., Ltd.
Where
South Korea7 sites in 1 countryChoose a country to see its sites
Trial code
Status
Active, not recruiting
Phase
Phase 2
People taking part
135 people, planned
Started
17 Apr 2026
Expected to end
Jan 2027
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Shingrix
  • CVI-VZV-001
Record updated
28 October 2026

Who can take part

Age
50 years and older
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 2 criteriaShow less

Who can take part

  • Participants must meet all of the following criteria:; Healthy adults aged 50 years or older; Able to understand the study procedures and provide written informed consent; Females and males of reproductive potential must agree to use medically acceptable contraception until 3 months after the last vaccination; Females of childbearing potential must have a negative pregnancy test prior to vaccination

Who cannot take part

  • Participants meeting any of the following criteria will be excluded:; History of herpes zoster prior to screening; History of severe allergic reaction to vaccines or vaccine components; Known immunodeficiency or immune dysfunction; Prior vaccination with varicella or herpes zoster vaccine; Use of immunosuppressive therapy or systemic steroids that may affect immune response; Positive test for HCV, HBV, or HIV at screening; Pregnant or breastfeeding women; Any medical condition that, in the opinion of the investigator, would make participation unsafe or interfere with study evaluation

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

To evaluate the immunogenicity of the investigational product (IP) in healthy adults aged 50 years or older and to explore differences in immune responses between the experimental and control groups, and to determine the optimal dose of the IP.

The 3 groups in the trial

  • CVI-VZV-001 Low DoseTreatment being tested

    Participants receive two doses of the investigational herpes zoster vaccine CVI-VZV-001 at the low dose level administered intramuscularly on Day 0 and Week 8.

    Treatment: CVI-VZV-001

  • CVI-VZV-001 High DoseTreatment being tested

    Participants receive two doses of the investigational herpes zoster vaccine CVI-VZV-001 at the high dose level administered intramuscularly on Day 0 and Week 8.

    Treatment: CVI-VZV-001

  • ShingrixExisting treatment, for comparison

    Participants receive two doses of the licensed herpes zoster vaccine Shingrix administered intramuscularly on Day 0 and Week 8.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Multicenter, Active-controlled, Randomized, Double Blinded, Parallel, Phase II Study to Assess the Immunogenicity and Safety of CVI-VZV-001 in Healthy Adults Aged 50 Years and Above
Record updated
28 October 2026